Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03530852 · ClinicalTrials.gov registry record · NA
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
A NA study of Short Bowel Syndrome and Malabsorption, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03530852 is a NA study of Short Bowel Syndrome and Malabsorption that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 32 participants, below the 183-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03530852, a NA study of Short Bowel Syndrome and Malabsorption, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition
Conditions Studied
Interventions
- DEVICE Relizorb
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2028-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03530852
The ClinicalTrials.gov registry entry for NCT03530852 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (83% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Relizorb is the first listed.
NCT03530852 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03530852 about?
NCT03530852 is a clinical study titled "A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB". Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver fa...
What is the current status of trial NCT03530852?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2018-11-21. Estimated completion is 2028-09-30.
What conditions does trial NCT03530852 study?
This clinical trial studies the following conditions: Short Bowel Syndrome, Malabsorption.
What interventions are being tested in trial NCT03530852?
The interventions under investigation include: Relizorb (DEVICE).
Who is sponsoring clinical trial NCT03530852?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03530852 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
RECRUITING · NA
-
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
RECRUITING · Early Phase 1
-
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
RECRUITING · Phase 2
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Registry for Participants With Short Bowel Syndrome
ACTIVE NOT RECRUITING
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.